Funding Opportunities

PDBP Funding opportunities (FOAs) support discovery projects designed to promote the identification of promising diagnostic and progression biomarkers for Parkinson's disease.

Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

Annoucement Type:
Reissue of PAR-18-550 - Analytical Validation of a Candidate Biomarker for Neurological Disease (U01) (Clinical Trial Optional)
Application Due Date:
Activity Code:
U01 Research Project – Cooperative Agreements
Letter of Intent Due Date:
FOA Number:
PAR-21-056
Contact:
Mary Ann Pelleymounter & Carol Taylor-Burds

Funding Opportunity Purpose

The purpose of this Program Announcement (PAR) is to enable analytical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous validation of analytical methods for biomarker measurements, which should include evaluation of the detection method, its performance characteristics, and the optimal conditions that will generate reproducibility and accuracy consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed, and 3) the research and/or clinical need and potential context of use has been identified.

Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)

Annoucement Type:
Reissue of PAR-18-664
Application Due Date:
Activity Code:
U01 Research Project – Cooperative Agreements
Letter of Intent Due Date:
FOA Number:
PAR-21-058
Contact:
Mary Ann Pelleymounter & Carol Taylor-Burds

Funding Opportunity Purpose

The purpose of this Program Announcement (PAR) is to enable clinical validation of strong candidate biomarkers for neurological and neuromuscular disorders and conditions. Specifically, the goal of this PAR is to enable the rigorous clinical validation of biomarker measurements within the clinical population of interest to establish the clinical sensitivity and specificity of the biomarker consistent with FDA guidelines. This PAR assumes that 1) a candidate biomarker has already been identified, 2) detection method technology has already been developed and analytically validated, and 3) the research and/or clinical need and potential context of use has been identified.

NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)

Annoucement Type:
Reissue of PAR-18-422
Activity Code:
UG3/UH3
FOA Number:
PAR-21-237
Contact:
Jeremy Brown, MD

Funding Opportunity Purpose

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications for investigator-initiated clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS) to establish the efficacy (or compare the effectiveness) of treatment interventions.  These Phase 3, Phase 4 or Pivotal trials must address questions within the mission and research interests of the NINDS and may include studies of drugs, biologics, and devices, as well as surgical, behavioral or rehabilitation therapies.

*Multiple due dates - see FOA